Why Arrowhead Shot Sky-High, While Chief Rival Ionis Toppled

Arrowhead Pharmaceuticals' triglycerides-buster hit the "best-case scenario" in two studies Wednesday, leading the stock to skyrocket.

Investors Business Daily • Jul 22, 2026

Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results for the global Phase 3 SHASTA-3 and SHASTA-4 clinical studies of plozasiran in patients with severe hypertriglyceridemia (sHTG), a condition that significantly increases the risk of acute pancreatitis (AP), which is associated with repeated hospital admissions and can be fatal. SHASTA-3 and SHASTA-4 successfully met the primary endpoint of triglyceride reduction versus placebo and m.

Business Wire • Jul 22, 2026

Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) stock is trading higher on Wednesday as the company revealed successful topline outcomes from its late-stage SHASTA-3 and SHASTA-4 trials evaluating plozasiran in individuals suffering from severe hypertriglyceridemia.

Benzinga • Jul 22, 2026

Arrowhead Pharmaceuticals: Redemplo Meets High Expectations In SHTG Trials

Arrowhead Pharmaceuticals reported positive phase 3 results for Redemplo, achieving 79-81% triglyceride reductions and significant acute pancreatitis risk reduction in severe hypertriglyceridemia. Redemplo demonstrates strong efficacy, quarterly dosing, and a favorable safety profile versus Ionis' Tryngolza, positioning ARWR for leadership in the SHTG market. Tryngolza has a first-mover advantage and administration with an autoinjector versus the current prefilled syringe for Redemplo, but ARWR expects to have an autoinjector as well.

Seeking Alpha • Jul 22, 2026

Arrowhead: Stock Up On SHTG Data - No Ceiling On Valuation Growth Potential

Arrowhead Pharmaceuticals surged nearly 20% after strong Phase 3 results for plozasiran in severe hypertriglyceridemia, showing 79–81% triglyceride reductions and significant acute pancreatitis risk reduction. Plozasiran's quarterly dosing, robust efficacy, and favorable safety profile position ARWR to challenge Ionis's Tryngolza in the lucrative sHTG market, with regulatory filings planned before year-end. ARWR's TRIM platform is attracting major partnerships and milestone payments, with a pipeline spanning obesity, cardiovascular, and metabolic diseases, supporting long-term revenue growth potential.

Seeking Alpha • Jul 22, 2026

These major drug stocks rally after Trump's zero tariff announcement

President Donald Trump has announced that all generic drugs imported into the United States would continue to enjoy a zero-percent tariff for another two years, sending major drug stocks up.

Finbold • Jul 22, 2026

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 4, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 third quarter ended June 30, 2026.Webcast and Conference Call DetailsInvestors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hour.

Business Wire • Jul 21, 2026

This Arrowhead Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga • Jul 14, 2026

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Cardiometabolic Pipeline and Clinical Development Programs Transcript

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Cardiometabolic Pipeline and Clinical Development Programs Transcript

Seeking Alpha • Jun 29, 2026

3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree

Large-cap pharma is back in the deal market. AbbVie's (NASDAQ: ABBV | ABBV Price Prediction) pending acquisition of Apogee Therapeutics signaled that big buyers will pay up for de-risked clinical assets.

24/7 Wall Street • Jun 25, 2026